{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:46:19Z","timestamp":1791506779346,"version":"4.3.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006342","name":"Association Vaincre la Mucoviscidose","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005413","name":"Universit\u00e9 Paris Descartes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005413","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jcf.2022.01.012","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T10:49:09Z","timestamp":1643798949000},"page":"489-496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis"],"prefix":"10.1016","volume":"21","author":[{"given":"Cl\u00e9mence","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Reynaud-Gaubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Hamidfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Durieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marl\u00e8ne","family":"Murris-Espin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Danner-Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Chiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Douvry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Grenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Mely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Ramel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Montcouquiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydie","family":"Lemonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esp\u00e9rie","family":"Burnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Paillasseur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2022.01.012_bib0001","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2022.01.012_bib0002","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1164\/rccm.201303-0429OC","article-title":"Survival benefit of lung transplant for cystic fibrosis since lung allocation score implementation","volume":"187","author":"Thabut","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jcf.2022.01.012_bib0003","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02443-2019","article-title":"Re-imagining cystic fibrosis care: next generation thinking","volume":"55","author":"Rang","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2022.01.012_bib0004","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2022.01.012_bib0005","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jcf.2022.01.012_bib0006","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jcf.2022.01.012_bib0007","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00082-2019","article-title":"Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles","volume":"5","author":"Taylor-Cousar","year":"2019","journal-title":"ERJ Open Res"},{"issue":"10212","key":"10.1016\/j.jcf.2022.01.012_bib0008","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2022.01.012_bib0009","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2022.01.012_bib0010","article-title":"Safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor for \u226524 weeks in people with CF and \u22651 F508del allele: interim results of an open-label phase three clinical trial","author":"Griese","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jcf.2022.01.012_bib0011","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2022.01.012_bib0012","article-title":"Ethical dilemma: elexacaftor-tezacaftor-ivacaftor or lung transplantation in cystic fibrosis and end-stage lung disease?","author":"Breuer","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2022.01.012_bib0013","article-title":"The impact of the high emergency lung transplantation program in cystic fibrosis in France: insight from a comparison with Canada","author":"Coriati","year":"2021","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.jcf.2022.01.012_bib0014","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jcf.2020.02.015","article-title":"Cystic fibrosis foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease","volume":"19","author":"Kapnadak","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2022.01.012_bib0015","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1164\/rccm.201507-1281OC","article-title":"Morphometric analysis of explant lungs in cystic fibrosis","volume":"193","author":"Boon","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jcf.2022.01.012_bib0016","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1183\/13993003.01918-2015","article-title":"Revel MP. Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor","volume":"48","author":"Chassagnon","year":"2016","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.jcf.2022.01.012_bib0017","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/thoraxjnl-2020-215556","article-title":"Longitudinal effects of ivacaftor and medicine possession ratio in people with the Gly551Asp mutation: a 5-year study","volume":"76","author":"Mitchell","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2022.01.012_bib0018","article-title":"Major decrease in lung transplantation for patients with cystic fibrosis in France","author":"Martin","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcf.2022.01.012_bib0019","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcf.2019.03.002","article-title":"Lung transplant referral for individuals with cystic fibrosis: cystic fibrosis foundation consensus guidelines","volume":"18","author":"Ramos","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.01.012_bib0020","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/621342","article-title":"Practical guidelines: lung transplantation in patients with cystic fibrosis","volume":"2014","author":"Hirche","year":"2014","journal-title":"Pulm Med"},{"key":"10.1016\/j.jcf.2022.01.012_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.healun.2021.07.005","article-title":"Consensus document for the selection of lung transplant candidates: an update from the international society for heart and lung transplantation","author":"Leard","year":"2021","journal-title":"J Heart Lung Transplant"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322000327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322000327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:47:15Z","timestamp":1761601635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199322000327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1569199322000327"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2022.01.012","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2022.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}